Earnings Call Snapshots: Vanda, Jazz, WuXi, Lundbeck
This article was originally published in The Pink Sheet Daily
Executive Summary
Vanda Pharmaceuticals is gearing up to launch its atypical antipsychotic Fanapt in the fourth quarter, after its approval in May; meanwhile Jazz Pharmaceuticals is looking ahead to commercial plans for its fibromyalgia candidate JZP-6 (sodium oxybate), with an NDA filing expected this year.
You may also be interested in...
WuXi PharmaTech Marks Second Quarter Of Earnings Rebound Following 2008's Devastating Loss, Opens New Drug Safety Testing Center
BEIJING - After recording a massive loss for 2008, WuXi PharmaTech, China's leading pharmaceutical contract research organization, posted a second consecutive quarter of earnings growth in the April-June period of this year
Cash-Strapped Jazz Gets Stock Bump From Data On Fibromyalgia Candidate
Jazz Pharmaceuticals' stock price increased 39 percent on June 25, following the second announcement in a week of a successful Phase III trial for its fibromyalgia candidate, JZP-6 (sodium oxybate). The company's share price quickly retreated, dropping 56 cents on June 26 after analysts at Barclay's Capital downgraded the company because of concerns related to its financial health. Still the 21 percent increase in share value could position the specialty pharma to raise badly needed funds, given it has dwindling cash and defaulted on two recent quarterly interest payments on outstanding debt
Reimbursement, Patient Switches Create Entry Point For Vanda’s Fanapt
Launching a "me too" product with a serious safety risk in a crowded field is not an easy task. But with the right profile and the right expectations, Vanda may have found the perfect entry point for its atypical antipsychotic Fanapt (iloperidone)